American Well Corp (AMWL) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. American Well Corporation is a leading enterprise software company enabling digital delivery of care. The company operates as a single reporting segment, providing the Amwell Platform for hybrid care delivery to health systems, health plans, and government entities. As of March 31, 2026, the company powered digital care programs for approximately 50 health plans and 80 health systems.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $54,883 | $66,833 |
| Net Loss | $(10,301) | $(18,356) |
| Net Loss Attributable to AMWL | $(10,886) | $(18,704) |
| Loss Per Share (Basic & Diluted) | $(0.66) | $(1.19) |
| Operating Cash Flow | $(983) | $(25,108) |
| Cash and Cash Equivalents | $179,207 | $222,411 |
| Total Debt | $0 | $0 |
| Adjusted EBITDA | $(3,080) | $(12,238) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 18% ($11.9 million) year-over-year. This was driven by a $7.3 million decrease in subscription revenue due to timing of recognition and a $6.9 million decrease in "Other" revenue (professional services). These were partially offset by a $2.3 million increase in visit revenue.
- Expense Reductions: Total costs and operating expenses decreased by 26% ($24.9 million). Significant reductions included:
- R&D: Down 44% ($9.7 million) due to headcount reductions (29%) and lower stock-based compensation.
- Sales & Marketing: Down 38% ($4.8 million) due to headcount reductions (53%) and reduced consulting/conference spend.
- G&A: Down 24% ($5.5 million) driven by lower employee costs and stock-based compensation.
- Divestiture Gain: The company recognized a $7.0 million net gain on divestiture in Q1 2026 related to contingent consideration from the sale of its APC business (telepsychiatry). In Q1 2025, the gain was $10.7 million.
- Impairment Charge: A one-time impairment charge of $3.4 million was recorded for the abandonment of the corporate headquarters right-of-use asset.
- Visit Volume: Total quarterly visits decreased to 1.05 million in Q1 2026 from 1.3 million in Q1 2025.
Guidance, Outlook, and Risks
- Strategic Transformation: Management continues to execute strategic transformation actions, including headcount reductions and lease abandonments, to align cost structure with revenue. Remaining costs for these actions are estimated at $6.2 million.
- Liquidity: The company holds $179.2 million in cash and cash equivalents with no debt. Management believes this is sufficient to meet working capital needs for at least the next 12 months.
- Key Risks:
- History of losses and uncertainty regarding achieving profitability.
- Concentration of revenue: Two clients represented 42% and 16% of total revenue in Q1 2026.
- Regulatory changes in healthcare reimbursement and privacy laws.
- Continuation of the Defense Health Agency relationship beyond July 2026.
- Unusual Items: The financial results include non-recurring items such as the $3.4 million lease impairment and the $7.0 million gain on divestiture.
Investor Verification Checklist
- Revenue Concentration: Verify the stability of the top two clients, which accounted for 58% of Q1 2026 revenue.
- Cost Structure Sustainability: Assess whether the significant expense reductions (driven by 30-53% headcount cuts in various departments) are sustainable without impacting future growth or platform development.
- Divestiture Proceeds: Confirm the timing and realization of the remaining contingent consideration from the APC divestiture.
- Visit Volume Trends: Monitor the decline in total visit volume (1.05M vs 1.3M) and its impact on future fee-for-service revenue.
- Legal Accruals: Review the $8.65 million in accrued legal expenses, of which $5.2 million relates to a specific case, for potential future liabilities.